A European randomised Phase 3 study to assess the efficacy and safety of TOOKAD� Soluble for localised prostate cancer compared to Active Surveillance
Read time: 1 mins
Last updated:17th Aug 2010
To assess the impact of TOOKAD® Soluble VTP on the rate of absence of definite cancer using patients on active surveillance as a comparison (co-primary objective A) and to determine the difference in risk of treatment failure associated with observed histological progression of disease in men with low risk prostate cancer who undergo TOOKAD® Soluble VTP compared to men on active surveillance (co-primary objective B).
|Study start date||2010-08-17|